Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy

Resolution of chronic hepatitis C is considered when serum HCV RNA becomes repeatedly undetectable and liver enzymes normalize. However, long-term persistence of HCV following therapy with pegylated interferon-α/ribavirin (PegIFN/R) was reported when more sensitive assays and testing of serial plasm...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2013-11, Vol.8 (11), p.e80078
Main Authors: Chen, Annie Y, Zeremski, Marija, Chauhan, Ranjit, Jacobson, Ira M, Talal, Andrew H, Michalak, Tomasz I
Format: Article
Language:English
Subjects:
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Biopsy
Female
Gastroenterology
Gene sequencing
Genomes
Health sciences
Hepacivirus - genetics
Hepacivirus - isolation & purification
Hepacivirus - physiology
Hepatitis
Hepatitis C
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - virology
Hepatology
Humans
Infections
Interferon
Interferon-alpha - administration & dosage
Interferon-alpha - therapeutic use
Limit of Detection
Liver
Lymphoid cells
Male
Medicine
Mutation
Patients
Peripheral blood mononuclear cells
Polyethylene Glycols - administration & dosage
Polyethylene Glycols - therapeutic use
Recombinant Proteins - administration & dosage
Recombinant Proteins - therapeutic use
Replication
Ribavirin
Ribavirin - administration & dosage
Ribavirin - therapeutic use
Ribonucleic acid
RNA
RNA viruses
RNA, Viral - blood
Therapy
Virology
Virus Replication
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Resolution of chronic hepatitis C is considered when serum HCV RNA becomes repeatedly undetectable and liver enzymes normalize. However, long-term persistence of HCV following therapy with pegylated interferon-α/ribavirin (PegIFN/R) was reported when more sensitive assays and testing of serial plasma, lymphoid cells (PBMC) and/or liver biopsies was applied. Our aim was to reassess plasma and PBMCs collected during and after standard PegIFN/R therapy from individuals who became HCV RNA nonreactive by clinical testing. Of particular interest was to determine if HCV genome and its replication remain detectable during ongoing treatment with PegIFN/R when evaluated by more sensitive detection approaches. Plasma acquired before (n = 11), during (n = 25) and up to 12-88 weeks post-treatment (n = 20) from 9 patients and PBMC (n = 23) from 3 of them were reanalyzed for HCV RNA with sensitivity
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0080078